LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

LLY

802.55

-2.25%↓

UNH

569.62

+1.64%↑

JNJ

160.55

+0.48%↑

MRK

125.13

-0.6%↓

ABBV

185.08

+1.61%↑

Home・Stock List・Novo Nordisk A-S

Novo Nordisk A-S

Closed

Sector Healthcare

126.83 -0.63

Buy Sell

Overview

Share price change

24h

Current

Min

126.32

Max

128.23

Key metrics
By Trading Economics
Income	2.9B 25B
Sales	-514M 65B
P/E Sector Avg	47.57 79.786
EPS	5.68
Profit margin	38.879
EBITDA	7.5B 37B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+12.9 upside

Market Stats
By TradingEconomics
Market Cap	-5.1B 478B
Previous open	127.46
Previous close	126.83

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

126.83 / 133.18 Support & Resistance

Novo Nordisk A-S Chart

Related News

26 Jun 2024, 20:55 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million

3 May 2024, 13:51 UTC

Acquisitions, Mergers, Takeovers

FTC Seeks More Info On $16.5 Billion Novo/Catalent Deal

19 Jul 2024, 11:00 UTC

Top News

Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ

19 Jul 2024, 10:50 UTC

Major News Events

Dow Jones Futures: Netflix Subscribers Jump As Tesla, Nvidia Resilient; President Biden Buzz Heats Up -- IBD

15 Jul 2024, 09:30 UTC

Top News

The New Holy Grail for Weight-Loss Drugs Is Sleep Apnea -- WSJ

4 Jul 2024, 12:04 UTC

Market Talk

Novo Nordisk's Weight-Loss Drug Retains Safety Profile Despite Concerns -- Market Talk

3 Jul 2024, 08:59 UTC

Top News

These Stocks Are Moving the Most Today: Tesla, Paramount, Nvidia, Constellation Brands, and More -- Barrons.com

2 Jul 2024, 11:20 UTC

Market Talk

Novo Nordisk Likely to Raise Sales Target, Set EBIT at Lower End of Range -- Market Talk

2 Jul 2024, 10:00 UTC

Top News

Wegovy Outspends TV Advertisers in June Ahead of More Weight-Loss Competition -- WSJ

28 Jun 2024, 21:32 UTC

Top News

The Score: Rivian, Amazon, Trump Media and More Stocks That Defined the Week -- WSJ

28 Jun 2024, 12:01 UTC

Market Talk

Novo Nordisk Fully Valued Amid Limited Longer-Term Visibility -- Market Talk

27 Jun 2024, 13:19 UTC

Market Talk

Earnings

Novo Nordisk Shows Its Vulnerable Side After Drug Trial Failure -- Market Talk

26 Jun 2024, 20:14 UTC

Acquisitions, Mergers, Takeovers

2seventy Bio: Divestiture Will Include Transfer of 2seventy Bio's megaTAL Technology and License to Underlying Intellectual Property >TSVT

26 Jun 2024, 11:00 UTC

Top News

Acquisitions, Mergers, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

20 Jun 2024, 20:16 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 18:51 UTC

Earnings

Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com

20 Jun 2024, 18:09 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- Update

20 Jun 2024, 11:00 UTC

Top News

Why Wall Street Is Chasing Ozempic Wannabes -- Heard on the Street -- WSJ

7 Jun 2024, 11:55 UTC

Top News

Germany's Merck Bets on AI Drug-Design Partnerships, Rules Out Acquisitions - Interview

24 May 2024, 13:53 UTC

Top News

Ozempic Slows Kidney Disease, Novo Nordisk Study Finds -- Update

21 May 2024, 11:04 UTC

Earnings

Acquisitions, Mergers, Takeovers

Why Jamie Dimon's Buyback Bombshell Is a Warning -2-

21 May 2024, 11:04 UTC

Earnings

Acquisitions, Mergers, Takeovers

Why Jamie Dimon's Buyback Bombshell Is a Warning for Stocks, and 5 Other Things to Know Before the Market Opens -- Barrons.com

13 May 2024, 11:15 UTC

Market Talk

Earnings

Novo Nordisk's Wegovy Supply is Ramping Up -- Market Talk

9 May 2024, 12:00 UTC

Top News

Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled -- WSJ

3 May 2024, 14:43 UTC

Hot Stocks

Stocks to Watch Friday: Apple, Amgen, Exxon, Coinbase -- WSJ

3 May 2024, 12:31 UTC

Market Talk

Earnings

Novo Nordisk Sentiment Dampened by Wegovy Price Cuts -- Market Talk

3 May 2024, 10:59 UTC

Acquisitions, Mergers, Takeovers

Why Apple's Nascent Rally Could Be Stalled By Warren Buffett, and 5 Other Things to Know Today. -- Barrons.com

3 May 2024, 10:59 UTC

Acquisitions, Mergers, Takeovers

Why Apple's Nascent Rally Could Be Stalled By -2-

2 May 2024, 15:09 UTC

Earnings

Novo Nordisk, ING, Shell: European Stocks in the Spotlight -- WSJ

2 May 2024, 14:16 UTC

Earnings

Novo Nordisk's Wegovy Sales More Than Doubled. Why the Stock Is Falling. -- Barrons.com

Peer Comparison

Price change

Novo Nordisk A-S Forecast

Price Target

By TipRanks

12.9% upside

12 Months Forecast

Average 144.36 USD 12.9%

High 166 USD

Low 82.5 USD

Based on 9 Wall Street analysts offering 12 month price targets forNovo Nordisk A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Novo Nordisk A-S - Dist in the past 3 months.

Technical Score

By Trading Central

126.83 / 133.18Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

EBITDA

Operating profit

About Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.